XGN · Exagen Inc.
$4.45
+0.00 (+0.00%)
At close · Jul 29
Market Cap
$107.51M
Shares
24.16M
Exagen Inc. Earnings Call Transcripts
Every quarterly earnings call for Exagen Inc. (XGN) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲20.2%
$14.73M
−$8.10M
'22 Q3
22-11-14
▲1.2%
$12.84M
−$14.35M
'22 Q4
23-01-09
▲8%
$11.23M
−$7.69M
'23 Q1
23-05-15
▲85.9%
$14.14M
−$5.01M
'23 Q2
23-08-07
▼8.9%
$13.42M
−$5.42M
'23 Q3
23-11-13
▲7.2%
$13.77M
−$5.57M
'23 Q4
24-03-18
▲28.4%
$14.41M
−$3.36M
'24 Q1
24-05-13
▲6.6%
$15.06M
−$2.97M
'24 Q2
24-08-05
▼6.8%
$12.51M
−$5.03M
'24 Q3
24-11-21
▼0.8%
$13.65M
−$3.76M
'24 Q4
25-03-11
▲7.5%
$15.50M
−$3.75M
'25 Q1
25-05-05
▲14.2%
$17.20M
−$4.44M
'25 Q2
25-07-29
▲37.9%
$17.24M
−$7.09M
'25 Q3
25-11-04
▲21.8%
$16.63M
−$4.67M
'25 Q4
26-03-10
LATEST
▲11.7%
$17.31M
−$3.97M
'26 Q1
26-05-11
Conference
Investor event
2026-08-11
Canaccord Genuity Growth Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-04
Q2 2026 Earnings Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-11
Exagen Inc. Q1 FY2026 Earnings Call
Confident tone
ASP and revenue cycle execution
Myositis pipeline and product cadence
Profitability and adjusted EBITDA
Revenue
$17.31M
▲ 11.7% YoY Diluted EPS
$-0.17
Gross margin
59.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-10
Exagen Inc. Q4 FY2025 Earnings Call
Revenue
$16.63M*
▲ 21.8% YoY Gross margin
55.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Exagen Inc. Q3 FY2025 Earnings Call
Positive tone
Average Selling Price (ASP) trajectory
Rheumatoid arthritis biomarker launches (anti-PAD4, RA33)
Revenue cycle, appeals and payer education
Revenue
$17.24M
▲ 37.9% YoY Diluted EPS
$-0.31
Gross margin
58.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-29
Exagen Inc. Q2 FY2025 Earnings Call
Confident tone
Reimbursement and ASP Improvement
Novel Biomarker Launches and Pipeline
Clinical Utility and Patient Impact
Revenue
$17.20M
▲ 14.2% YoY Diluted EPS
$-0.21
Gross margin
60.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Exagen Inc. Q1 FY2025 Earnings Call
Confident tone
ASP and reimbursement progress
New biomarker launch and AVISE CTD momentum
Operational turnaround and culture
Revenue
$15.50M
▲ 7.5% YoY Diluted EPS
$-0.20
Gross margin
58.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-11
Exagen Inc. Q4 FY2024 Earnings Call
Positive tone
Clinical case studies and physician adoption
New biomarker launch (T cell and RA33)
Revenue and ASP growth
Revenue
$13.65M*
▼ 0.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-21
Exagen Inc. Q3 FY2024 Earnings Call
Confident tone
Revenue and ASP performance
Path to profitability and cash flow positivity
ACR conference and clinical evidence
Revenue
$12.51M
▼ 6.8% YoY Diluted EPS
$-0.28
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-05
Exagen Inc. Q2 FY2024 Earnings Call
Confident tone
Profitability path and adjusted EBITDA improvement
AVISE CTD volume and ASP growth
Executive leadership transition
Revenue
$15.06M
▲ 6.6% YoY Diluted EPS
$-0.16
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Exagen Inc. Q1 FY2024 Earnings Call
Confident tone
AVISE CTD product enhancements and new markers
Volume recovery and ordering efficiencies
Expense management and guidance caution
Revenue
$14.41M
▲ 28.4% YoY Diluted EPS
$-0.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-18
Exagen Inc. Q4 FY2023 Earnings Call
Confident tone
AVISE CTD Core Product Performance
Average Selling Price (ASP) Improvement
Path to Profitability and Cashflow Breakeven
Revenue
$13.77M*
▲ 7.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-13
Exagen Inc. Q3 FY2023 Earnings Call
Revenue
$13.42M
▼ 8.9% YoY Diluted EPS
$-0.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Exagen Inc. Q2 FY2023 Earnings Call
Revenue
$14.14M
▲ 85.9% YoY Diluted EPS
$-0.28
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
Exagen Inc. Q1 FY2023 Earnings Call
Revenue
$11.23M
▲ 8% YoY Diluted EPS
$-0.44
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Exagen Inc. Q4 FY2022 Earnings Call
Revenue
$12.84M*
▲ 1.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Exagen Inc. Q3 FY2022 Earnings Call
Revenue
$14.73M
▲ 20.2% YoY Diluted EPS
$-0.47
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Exagen Inc. Q2 FY2022 Earnings Call
Revenue
$7.61M
▼ 40.4% YoY Diluted EPS
$-0.86
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Exagen Inc. Q1 FY2022 Earnings Call
Revenue
$10.39M
▼ 1.8% YoY Diluted EPS
$-0.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-22
Exagen Inc. Q4 FY2021 Earnings Call
Revenue
$12.69M*
▼ 45.9% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Exagen Inc. Q3 FY2021 Earnings Call
Revenue
$12.25M
Diluted EPS
$-0.42
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Exagen Inc. Q2 FY2021 Earnings Call
Revenue
$12.77M
▲ 42.7% YoY Diluted EPS
$-0.38
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Exagen Inc. Q1 FY2021 Earnings Call
Revenue
$10.59M
▲ 10.5% YoY
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-16
Exagen Inc. Q4 FY2020 Earnings Call
Revenue
$23.44M*
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Exagen Inc. Q3 FY2020 Earnings Call
Revenue
$
▼ 100% YoY
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-28
Exagen Inc. Q2 FY2020 Earnings Call
Revenue
$8.95M
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Exagen Inc. Q1 FY2020 Earnings Call
Revenue
$9.58M
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-25
Exagen Inc. Q4 FY2019 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls